

IN THE CLAIMS

1 - 2. (Canceled)

3. (Currently Amended) The method of Claim [[1]]7, wherein said mammal is a human.

4. (Canceled)

5. (Currently Amended) The method of Claim [[1]]7, wherein said antibody is a human, humanized, or chimeric antibody.

6. (Canceled)

7. (Currently Amended) A method of treating a mammal with inflammatory disease, comprising:

a) exposing a tissue sample ~~tissues~~ from said mammal to differing antibodies which bind to specific chemokines, wherein said chemokines are selected from the group consisting of CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10;

b) ~~identifying~~ determining a level of expression of each chemokine based on binding of the each of said antibodies and identifying an over-expressed chemokine in said tissue sample; and

c) administering to said mammal at least one antibody specific for[[an]]said over-expressed chemokine, ~~wherein said chemokine is~~

~~selected from the group consisting of: CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10.~~

8. (Currently Amended) The method of Claim 7, wherein in step c, said antibody is administered directly ~~to the affected~~ into an inflamed tissue.

9. (Previously Presented) The method of Claim 7, wherein in step c, said antibody is administered parenterally.

10. (Previously Presented) The method of Claim 7, wherein said antibody is administered in a liquid carrier.

11. (Previously Presented) The method of Claim 7, wherein said antibody is administered on a solid support.

12. (Currently Amended) A method of treating a mammal with inflammatory disease, ~~by the steps of comprising:~~

a) ~~identifying~~determining the level of particular chemokines in a tissue sample in said mammal using PCR, wherein said chemokines are selected from the group consisting of CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10;

b) identifying an over-expressed chemokine; and

~~[[b]]~~c) administering to said mammal at least one antibody ~~specifically binds to an~~ specific for said over-expressed chemokine, ~~wherein said chemokine is selected from the group~~ consisting of:

~~CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2 and CCR10.~~

13. (Currently Amended) The method of Claim 12, wherein said antibody is administered directly ~~to the affected~~ into an inflamed tissue.

14. (Previously Presented) The method of Claim 12, wherein said antibody is administered systemically.

15. (Previously Presented) The method of Claim 12, wherein said antibody is administered on a solid support.

16 - 17. (Canceled)

18. (Currently Amended) The method of Claim 7, wherein said ~~antibody~~ at least one antibody specific for said over-expressed chemokine is specific for CXCL10.

19. (Currently Amended) The method of Claim 12, wherein said ~~antibody~~ at least one antibody that is specific for said over-expressed chemokine is specific for CXCL10.

20. (New) The method of Claim 12, wherein said antibody is a human, humanized, or chimeric antibody.

21. (New) The method of Claim 7, wherein said inflammatory disease is selected from the group consisting of anaphylaxis, septic shock, arthritis, asthma, allergies, atherosclerosis, bronchitis, chronic pulmonary obstructive disease, delayed type hypersensitivity, dermatitis, diabetes, graft rejection, Grave's disease, Hashimoto's thyroiditis, inflammatory bowel diseases, interstitial cystitis, multiple sclerosis, myasthenia gravis, pneumonitis, psoriasis, nephritis, rhinitis, spondyloarthropathies, scleroderma, systemic lupus erythematosus, and throiditis.

22. (New) The method of Claim 12, wherein said inflammatory disease is selected from the group consisting of anaphylaxis, septic shock, arthritis, asthma, allergies, atherosclerosis, bronchitis, chronic pulmonary obstructive disease, delayed type hypersensitivity, dermatitis, diabetes, graft rejection, Grave's disease, Hashimoto's thyroiditis, inflammatory bowel diseases, interstitial cystitis, multiple sclerosis, myasthenia gravis, pneumonitis, psoriasis, nephritis, rhinitis, spondyloarthropathies, scleroderma, systemic lupus erythematosus, and thyroiditis.